tbuckley/cabot-search huggingface dataset:
How many liver resections for multinodular hepatocellular carcinoma are not radical resections?
Authors: Yiqun Yan, Jing Li, Liang Huang
Journal: Journal of Clinical Oncology (2015)

e15163 Background: Previous studies have reported good results of hepatectomy for resectable multinodular hepatocellular carcinoma (HCC). However, many of these patients experienced very early recurrence after hepatectomy, which was hard to distinguish from remaining tumors in the liver during hepatectomy. This prospective cohort study aimed to observe that how many patients had remaining tumors in the liver after hepatectomy for multinodular HCC, and to investigate the factors relating to that. Methods: From October 2009 to September 2012, 987 consecutive patients with multinodular HCCs were screened. Among them, 151 patients who received hepatectomy were prospectively enrolled in the study. All the patients were given digital substraction angiography (DSA) one month after hepatectomy. That of remaining tumor in the liver was definded as that there was tumor staining in the liver with rapid filling and fast wash out during angiography. Results: Fifty-eight patients (38.4%) had remaining tumor in the liver during DSA one month after hepatectomy. Among them, 31 patients had one tumor while 27 patients had multiple. On univariate analysis, younger age, larger tumor size, AFP > 400 ug/L and macrovascular invasion were significantly correlated with positive findings during DSA after hepatectomy (P = 0.029, P = 0.009, P = 0.012 and P = 0.001, respectively). Only macrovascular invasion remained as a predictive factor on multivariate analysis (HR, 11.46; 95% CI, 2.80-55.46, P = 0.005). Conclusions: For multinodular HCC with macrovascular invasion, hepatectomy can not achieve radical resection.
Abstract 91: Genome-wide Identification and Characterization of Cardiac Hypertrophy-related Long Noncoding RNAs in Mice
Authors: Zhanpeng Huang, Gengze Wu, Jian-Hua Yang, Jian Ding, Jinghai Chen, Zhiqiang Lin, Stavros G Drakos, Craig H Selzman, Jan Kyselovic, William T Pu, Liang-Hu Qu, Chunyu Zeng, Da-Zhi Wang
Journal: Circulation Research (2016)

Long noncoding RNAs (LncRNAs) are RNA transcripts longer than 200 nucleotides that lack protein-coding potential. Although thousands of lncRNAs have been identified, only a few have been linked to cardiac gene expression and function. In this study, we identified, from genome-scale RNA-seq data, 12 candidate lncRNAs associated with cardiac hypertrophy (CH-lncRNAs). The expression of these lncRNAs was altered in mouse models of cardiac hypertrophy induced by transverse aortic constriction (TAC)- or CnA transgene. To determine the function of these lncRNAs, we developed an adeno-associated virus serotype 9 (AAV9)-based functional screening in postnatal mice. An AAV9:cTNT vector, in which the cardiac troponin T (cTNT) promoter was used to direct cardiac-specific expression of target genes, was utilized to overexpress or knockdown candidate lncRNAs in mouse hearts. Postnatal day 1 wild type or CnA transgenic pups were injected with AAV9 viruses and cardiac function was measured one and two months later. Thus far, we have tested 15 candidate lncRNAs for both gain- and loss-of-function studies. Among them, two lncRNAs were demonstrated regulating hypertrophy growth when knocked down. Finally, we identified the human homologues of CH-lncRNA through analyzing the conservation of the promoter regions of lncRNA genes. We showed that the expression of these human CH-lncRNA was dysregulated in human diseased hearts, suggesting the functional conservation of these lncRNAs in cardiac disease. Our study therefore demonstrated that lncRNAs are important regulator of cardiac hypertrophy and disease.
Utilization of intravenous bisphosphonates (IVBs) in patients with bone metastases (BMets) secondary to breast, lung, or prostate cancer (BC, LC, PC).
Authors: May Hagiwara, Ze Cong, Karen Chung, Thomas E. Delea
Journal: Journal of Clinical Oncology (2013)

e20665 Background: Cancer patients with BMets are predisposed to skeletal complications. Bone targeted therapies such as denosumab or IVBs reduce the risk of these complications. The objective of this study was to characterize patterns of IVB use in these patients. Methods: This was a retrospective, observational study using the Thomson MedStat MarketScan Commercial and Medicare databases (9/02 - 6/11). Subjects were all persons with ≥1 claim with a diagnosis (Dx) of BC, LC, or PC and ≥1 claim with a Dx of BMets. The date of first BMet Dx claim was the “index date”. Key exclusion criteria were Dx of other primary cancer, receipt of IVB pre-index, or &lt;6 mos continuous enrollment pre-index. Cumulative incidence of treatment initiation (first IVB claim, death as competing risk), interruption (gap of &gt;60 days between IVB claims, discontinuation as competing risk), and discontinuation (last IVB claim) were analyzed. Results: Cumulative incidence of initiation of IVB at 12 mos post-index was greatest for BC followed by PC and LC (Table). IVB treatment interruption at 12 mos ranged from 16% (LC) to 31% (PC). IVB treatment discontinuation at 12 mos ranged from 46% (BC) to 83% (LC). Cumulative incidence of initiation of IVB at 12 mos declined with age in all tumor types: e.g., in BC, from 62% at age&lt;50 years to 47% at age 75+ years. Conclusions: IVBs are used more frequently in patients with BMets secondary to BC than PC or LC. Many patients interrupt or discontinue IVB therapy within 12 mos. of initiation, potentially impacting effectiveness. [Table: see text]
Intraoperative Surgical Performance Measurement and Outcomes
Authors: Rajesh Aggarwal
Journal: JAMA Surgery (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
08.12 Activated human b cells modulate cytokine production and differentiation of multipotent mesenchymal stromal cells
Authors: Panagiotis Gitsioudis, Bastian Resch, Patrick Horn, Rainer Saffrich, Lars Tykocinski, Hanns-Martin Lorenz, Theresa Tretter
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Multipotent mesenchymal stromal cells (MSC) are well known for their multilineage potential and immunosuppressive properties. They might be a useful alternative for treatment of chronic inflammatory diseases. Little is known however, in how far the inflammatory cellular environment eg, activated lymphocytes and their mediators might interfere with their function. Aim of the study is to investigate the influence of activated B cells on immunologic and regenerative properties of MSC. <h3>Materials and methods</h3> Highly purified CD19+B-cells were separated from PBMC by magnetic cell sorting. B-cells were polyclonally stimulated by B-cell-receptor cross-linking and IL-2 and cocultured with bone marrow derived MSC for various time periods. Cytokines were quantified after 72 hour by intracellular flow cytometry or in cell culture supernatants by ELISA and B cell division by flow cytometric methods at d5. Differentiation potential of MSC was assessed by use of established differentiation media in absence or presence of B cell culture supernatant. After 21 days differentiation into the osteogenic or adipogenic lineage was determined by fluorescence microscopy and quantified with ImageJ software. <h3>Results</h3> In MSC-B-cell cocultures the MSC-specific production of IL-6 and IL-8 increased by more than 100-fold compared to MSC single cultures. In contrast, B cell-specific production of TNF-alpha, Immunoglobulins and B cell proliferation diminished in B-MSC cocultures by more than 50% suggesting an inhibitory feedback mechanism by activated MSC towards the B cells. Separation of B cells from MSC by semipermeable cell culture inserts (transwell) did not abolish observed effects, suggesting that soluble factors were the main mediators. Of note, addition of neutralising antibodies against the B cell specific cytokines TNF-alpha and IL-1-beta significantly reduced MSC cytokine production in cocultures. B cells also influenced regenerative potential of MSC: in presence of B-cell supernatant MSC differentiation into the osteogenic lineage was significantly increased, accompanied by higher cell number, while differentiation into the adipogenic lineage was inhibited. <h3>Conclusions</h3> In presence of activated B cells MSC exert immunosuppressive effects.. However at the same time these MSC produce high amounts of proinflammatory cytokines and change their differentiation behaviour, suggesting an important influence of the cellular environment on MSC functions.
REPRODUCIBILITY OF THE DRGONIOMETER APP IN NORDIC HAMSTRING TEST ASSESSMENT
Authors: Stefano Vercelli, Alex Baldaccini, Francesco Sartorio, Elisabetta Bravini, Giorgio Ferriero
Journal: British Journal of Sports Medicine (2017)

Background The break-point angle (BPA) obtained during the Nordic Hamstring Test (NHT) can be used for preventive purposes to identify individuals with low eccentric hamstring strength. Video analysis is the preferred standard method, but there lacks an easily accessible and highly reproducible method for field use. Objective To establish the reproducibility (reliability and agreement) of the smartphone application ‘DrGoniometer’ (DrG) for measuring BPA in healthy adults. Design Diagnostic study. Setting Clinical setting. Patients (or Participants) Five volunteers and four raters (two physiotherapists and two physiotherapy students). Interventions (or Assessment of Risk Factors) Ten NHT videos per subject were obtained by smartphone camera (total=50 videos). Raters independently measured the BPA, first using DrG app set in blind modality on two separate occasions (one week apart), then by standardized video analysis software on a PC. Main Outcome Measurements Intra- and inter-rater reliability of DrG was calculated with ICC (2,1) (95% IC). Longitudinal standard error of measurement (SEM) and inter-rater agreement within 5° and 10° were also calculated. The agreement of DrG with video analysis was expressed as 95% limits of agreement (LoA) with the Bland-Altman method. Results Intra- and inter-rater reliability of the DrG were excellent, with ICC=0.885 (95% IC=0.836–0.918) and .821 (95%IC=0.738–0.885), respectively. The SEM was 2°. All four raters had substantial inter-rater agreement within the limits of 5° (68% and 78%) and 10° (94% and 100%) for the DrG and video analysis methods, respectively. The agreement between the two methods was good, with 95% LoA equal to 13.4° (mean difference=1.0±6.7°). Conclusions DrG proved to be a highly reproducible method for measuring the BPA in the NHT in healthy subjects. Given its wide availability, low cost, and ease of use, the DrG app can be considered a good resource for field-based BPA measurement.
Parotid squamous cell carcinoma: Is it a primary or secondary?
Authors: M. A. Aboziada, A. Eisbruch
Journal: Journal of Clinical Oncology (2011)

e16002 Background: To evaluate patients with parotid squamous cell carcinoma (SCC) to see is it a primary or metastatic and determine the outcome of patients. Methods: Fifty-nine patients were identified with parotid SCC through the hospital database, patients' charts, imaging studies, and computerized notes of the University of Michigan. Results: Fifty patients diagnosed as metastatic SCC of parotid lymph nodes. However, 9 patients diagnosed as primary. Forty seven patients with metastatic SCC treated with surgery and post-operative radiotherapy. The median follow up of these patients was 33 months. The 3-year actuarial cause specific survival was 91%. The 3-year actuarial local recurrence free survival (LRFS) and disease free survival rate were79% and 77% respectively. Positive surgical margin after parotidectomy was the only factor that had statistically significant poor LRFS. Conclusions: The most common site of the primary tumor was a cutaneous SCC of the face. All patients should be considered for facial sparing radical parotidectomy and adjuvant radiotherapy. Neck dissection or elective neck irradiation for ipsilateral neck is recommended due to high occult LN metastasis. The addition of chemotherapy or targeted therapy may be beneficial and are points of research. Patients' characteristics. Metastatic SCC (50) No. (%) Primary SCC (9) No. (%) Clinical neck L.N Facial palsy Neck dissection Facial preservation Positive margins PNI Grade of disease Pathologic neck L.N Occult neck L.N spread Neck L.N. ECE Parotid RT Ipsilateral neck RT Bilateral neck RT Chemotherapy Local recurrence Neck recurrence Distant metastasis Cause specific death 8 (16) 2 (3) 44 (88) 34 (68) 19 (38) 13 (26) GI 6 (12) GII 30 (60) GIII 14 (28) 24 /44 (54) 16/36 (44) 9/24 (37) 47 (94) 42 (84) 2 13 (26) 11 (22) 0 2 (Lung) 4 3 (33) 1 (11) 7 (77) 3 (33) 3 (33) 4 (44) GI 2 (22) GII 2 (22) GIII 5 (56) 3/7 (42) 0/4 2/3 (66) 9 (100) 8 (88) 1 4 (44) 0 0 1 (Lung) 0 Abbreviations: SCC: squamous cell carcinoma; L.N: lymph node; PNI: perineural invasion; ECE: extracapsular extension; RT: radiotherapy.
OP0240 How strong are the associations of spondyloarthritis-related comorbidities with ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis? a register-based study from sweden
Authors: K Bengtsson, H Forsblad-d'Elia, E Lie, E Klingberg, M Dehlin, S Exarchou, U Lindström, J Askling, LT Jacobsson
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Spondyloarthritis (SpA), including ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated SpA (uSpA), is a cluster of rheumatic diseases with some common genetic risk factors. These genetic risk factors are likely to result in associations of varying degree with SpA-related comorbidities such as inflammatory bowel disease (IBD), psoriasis and anterior uveitis. There is also a known association between AS and conduction disturbances and aortic regurgitation. Comparative analyses in the same setting of the strengths of these associations with AS, PsA and uSpA are scarce. <h3>Objectives</h3> To assess the strengths of the associations of different SpA-related comorbidities with a diagnosis of AS, PsA and uSpA. <h3>Methods</h3> All patients, aged ≥18 years, with AS (n=3884), PsA (n=8706) and uSpA (n=2665) were identified 2001 through 2005, according to specified ICD codes from the Swedish Patient Register. The register contains diagnoses from all visits in inpatient and non-primary outpatient care. Each patient was matched by year of birth, sex and county to five general population (GP) controls identified in the Population Register. Occurrence of SpA-related comorbidities prior to 1 January 2006 were also retrieved from the Swedish Patient Register. Number and proportion of cases (n (%)) with a recorded SpA-related comorbidity prior to 1 January 2006 and corresponding prevalence ratio (PR) with 95% confidence interval (CI) were calculated, overall and stratified for sex. <h3>Results</h3> PRs for SpA-related comorbidities were significantly elevated in all SpA subtypes compared to their matched GP controls (Table). PRs were substantially elevated in AS, intermediately elevated in uSpA, whereas only moderately increased in PsA. The results were similar in the sex-stratified analyses (not shown). <h3>Conclusions</h3> The strongest associations of SpA-related comorbidities were seen with AS, closely followed by uSpA, compatible with a substantial shared etiology and phenotypical expression for patients given these two diagnoses, whereas the associations between PsA and the SpA-related comorbidities were considerably weaker. <h3>Disclosure of Interest</h3> None declared
真空支援脱細胞化:組織工学ヒト気管足場を生成するための加速されたプロトコル【Powered by NICT】
Authors: R Butler Colin, E Hynds Robert, Crowley Claire, H C Gowers Kate, Partington Leanne, J Hamilton Nicholas, Carvalho Carla, Plate Manuela, R Samuel Edward, J Burns Alan, Urbani Luca, A Birchall Martin, W Lowdell Mark, De Coppi Paolo, M Janes Sam
Journal: Biomaterials (2017)
05.13 Should we evaluate the bone mineral density in patients with head and neck tumours?
Authors: Raquel Hernández, Julia Uceda, Carmen Almeida, Jose L. Marenco, Jose Fuentes
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> The head and neck tumours are a heterogeneous group of diseases that affect the otolaryngology (ENT) sphere . It constitutes 2.9% of all new cancer cases. Predominantly affect older men aged 40 years. Smoking, excessive alcohol consumption, treatment with high doses of corticosteroids and malnutrition suffering after surgery and radiotherapy, involves a potential situation of accelerated bone loss in a young population with good long-term prognosis. <h3>Objective</h3> To describe the characteristics regarding risk factors and osteoporotic disease in patients with head and neck tumours. <h3>Material and methods</h3> An Observational study of a case series of patients with tumours of the head and neck joint monitoring in consultations of Rheumatology and Medical Oncology Hospital Valme area. We collected the following variables; age, sex, risk factors for osteoporosis and osteoporotic fracture, lateral radiography of lumbar and thoracic spine, and lumbar spine and hip bone densitometry <h3>Results</h3> 50 patients diagnosed whith head and neck tumours were included. Of these, 100% were male, with a mean age of 62 years at present. The most frequent location was the larynx in 55% of cases, followed by a 7% for those of tonsils and other locations of the oral cavity . Approximately a 16% of patients had a history of gastrointestinal pathology In relation to risk factors for both disease, tumour and osteoporosis we found : Also found two patients with vertebral fractures, one with osteoporosis and the second with osteopenia. Finally in relation to tumour pathology, 10% were stage II, candidates for treatment with radiation therapy compared with 90% remaining subsidiary of intensive treatment with chemotherapy, radiation therapy and high-dose corticosteroids. <h3>Conclusions</h3> In our sample, we found that up to 16.6% of patients and 7.1% had osteopenia or osteoporosis at baseline. Assuming that during treatment, they will suffer about 16% of loss weight, attached to treatment with high-dose corticosteroids, would justify develop measures for primary prevention of osteoporosis with a study and treatment of these patients.
A functional characteristic of cysteine‐rich protein 61: Modulation of myeloid‐derived suppressor cells in liver inflammation
Authors: Haiyan Zhang, Min Lian, Jun Zhang, Zhaolian Bian, Ruqi Tang, Qi Miao, Yanshen Peng, Jingyuan Fang, Zhengrui You, Pietro Invernizzi, Qixia Wang, M. Eric Gershwin, Xiong Ma
Journal: Hepatology (2017)

There is increasing awareness of the immunologic roles of liver mononuclear populations, including myeloid-derived suppressor cells (MDSCs). We took advantage of a large well-defined cohort of 148 patients with liver inflammation and 45 healthy controls to focus on the qualitative and quantitative characteristics of MDSCs. We investigated the frequency, phenotype, and functional capacities of MDSCs by using peripheral blood MDSCs in a cohort of 55 patients with primary biliary cholangitis (PBC), 40 with autoimmune hepatitis, 39 with chronic hepatitis B, 14 with nonalcoholic fatty liver disease, and 45 healthy controls. This was followed by a liver-targeted determination in 27 patients with PBC, 27 with autoimmune hepatitis, 20 with chronic hepatitis B, 14 with nonalcoholic fatty liver disease, and 6 controls. We then focused on mechanisms of this expansion with PBC as an example, using both ursodeoxycholic acid-naive and treated patients. HLA-DR-/low CD33+ CD11b+ CD14+ CD15- monocytic MDSCs were elevated in diseases characterized by liver inflammation compared to healthy controls. Using PBC as a focus, there was a significant correlation between levels of circulating MDSCs and disease-related biochemical markers (alkaline phosphatase, total bilirubin). We found higher amounts of MDSCs in patients with PBC who were responsive to ursodeoxycholic acid. MDSCs from PBC were found to manifest a potent immunosuppressive function. There was a significant correlation in the accumulation of hepatic MDSCs in the inflamed lesions of PBC with histologic changes, such as fibrosis. We also found that cysteine-rich protein 61 (CCN1), a highly expressed protein in impaired cholangiocytes and hepatocytes, contributes to MDSC expansion and MDSC inducible nitric oxide synthase-associated immune suppression.CCN1 modulates expansion and a suppressive function of MDSCs. Our data highlight the potential functions of CCN1 on MDSCs and suggest therapeutic implications in inflammatory liver diseases. (Hepatology HEPATOLOGY 2018;67:232-246).
Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis
Authors: Hadar Goldvaser, Tristan A Barnes, Boštjan Šeruga, David W Cescon, Alberto Ocaña, Domen Ribnikar, Eitan Amir
Journal: JNCI Journal of the National Cancer Institute (2017)

A number of randomized controlled trials (RCTs) have reported improvement in breast cancer outcomes from extending treatment with aromatase inhibitors (AIs) beyond the initial five years after diagnosis. However, the toxicity profile of extended AIs is uncertain.We identified RCTs that compared extended AIs to placebo or no treatment using MEDLINE and a review of abstracts from key conferences between 2013 and 2016. Odds ratios (ORs), 95% confidence intervals (CIs), absolute risks, and the number needed to harm (NNH) were computed for prespecified safety and tolerability outcomes including cardiovascular events, bone fractures, second cancers (excluding new breast cancer), treatment discontinuation for adverse events, and death without recurrence. All statistical tests were two-sided.Seven trials comprising 16 349 patients met the inclusion criteria. Longer treatment with AIs was associated with increased odds of cardiovascular events (OR = 1.18, 95% CI = 1.00 to 1.40, P = .05, NNH = 122), bone fractures (OR = 1.34, 95% CI = 1.16 to 1.55, P < .001, NNH = 72), and treatment discontinuation for adverse events (OR = 1.45, 95% CI = 1.25 to 1.68, P < .001, NNH = 21). Longer treatment with AIs did not influence the odds of either second malignancy (OR = 0.93, 95% CI = 0.73 to 1.18, P = .56) or deaths without breast cancer recurrence (OR = 1.11, 95% CI = 0.90 to 1.36, P = .34).Extended treatment with AIs is associated with an increased risk of cardiovascular events and bone fractures. There is no statistically significant increase in deaths without breast cancer recurrence among patients receiving longer treatment with AIs. These data should be taken into account when considering extended adjuvant AIs.
Treatment of Patients with Severe Congenital Protein C Deficiency in a Registry Study of Protein C Concentrate (Human)
Authors: Marilyn Manco-Johnson, Hans-Joerg Hertfelder, Theodosia A. Kalfa, Emmett H. Broxson, Lisa Bomgaars, Amy D. Shapiro, Dyck-Jones Jacqueline, Sandra Ehrle, Maureen Finnerty, David Gelmont, Leman Yel, Mahmoud Loghman-Adham
Journal: Blood (2016)